 |
|
Underutilized treatment for advanced ovarian cancer found to significantly improve survival
January 05, 2006According to a study published in the January 5 issue of the New England Journal of Medicine, women with Stage III ovarian cancer given a combination of intravenous (IV) and intra-abdominal chemotherapy, following the successful surgical removal of tumors, experienced a median survival time 16 months longer than women who received IV chemotherapy alone.
Intra-abdominal chemotherapy, also known as intraperitoneal (IP) chemotherapy, involves the delivery of anticancer drugs directly into the abdomen. This type of chemotherapy administration is underutilized, but significant evidence from this new study confirms the survival benefit of IP chemotherapy for most women with advanced ovarian cancer.
The study, conducted by Deborah K. Armstrong, MD, an assistant professor at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, and her colleagues, builds upon evidence from eight other clinical trials - including those conducted at Memorial Sloan-Kettering Cancer Center (MSKCC) - showing an overall survival period of approximately one year for women treated with IP chemotherapy after "optimal debulking" - surgery to remove most, if not all, of the cancer in the abdomen.
Based on this overwhelming evidence, the National Cancer Institute (NCI) will issue a clinical announcement on January 5 encouraging the administration of a combination of IV and IP chemotherapy to treat women with advanced ovarian cancer, who have undergone optimal surgical debulking.
After pioneering the first clinical trials of IP chemotherapy in the late 1980s, MSKCC is one of the most experienced centers with the largest volume of patients who have undergone the procedure. The Center has been using IP chemotherapy as a standard of care based on Dr. Armstrong's presentation at the American Society of Clinical Oncology's annual meeting in May 2005 and research conducted at MSKCC.
Patients who have undergo
Memorial Sloan-Kettering Cancer Center
Based on this overwhelming evidence, the National Cancer Institute (NCI) will issue a clinical announcement on January 5 encouraging the administration of a combination of IV and IP chemotherapy to treat women with advanced ovarian cancer, who have undergone optimal surgical debulking.
After pioneering the first clinical trials of IP chemotherapy in the late 1980s, MSKCC is one of the most experienced centers with the largest volume of patients who have undergone the procedure. The Center has been using IP chemotherapy as a standard of care based on Dr. Armstrong's presentation at the American Society of Clinical Oncology's annual meeting in May 2005 and research conducted at MSKCC.
Patients who have undergo
Memorial Sloan-Kettering Cancer Center
Advanced Ovarian Cancer Current Events and Advanced Ovarian Cancer News RSSNanoparticle-delivered 'suicide' genes slowed ovarian tumor growth
Nanoparticle delivery of diphtheria toxin-encoding DNA selectively expressed in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect this therapy could be tested in humans within 18 to 24 months, according to a report in Cancer Research, a journal of the American Association for Cancer Research.
International study supports new standard of treatment for women with advanced ovarian cancer
Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course.
Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
One of the shortcomings of a therapy that uses millions of identical antibodies to boost the immune system's attack on cancer cells is that many patients whose tumors recede in response to the treatment also experience serious inflammatory problems, such as severe diarrhea and rashes.
VEGF Trap shows activity in patients with advanced ovarian cancer
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.
Early results indicate radiofreqency ablation useful in treating ovarian cancer metastasis
Percutaneous radiofrequency ablation, a procedure that uses a high frequency electric current to kill tumor cells, is effective in achieving local control in selected patients with metastasis from ovarian cancer.
Mayo Clinic finds aggressive surgery best option for advanced-stage ovarian cancer patients
Mayo Clinic Cancer Center researchers report aggressive surgical removal of as much cancer as possible throughout the abdomen in ovarian cancer patients is the best option for most women.
Abdominal chemo boosts survival in ovarian cancer patients
A 50-year-old method for delivering chemotherapy directly into the abdomen is making a comeback as investigators have found that it increases survival-by more than a year-in some women with advanced ovarian cancer.
Gene expression profile helps predict chemotherapy response in ovarian cancer patients
A newly identified gene expression profile could help predict how patients with advanced ovarian cancer will respond to chemotherapy treatment.
Radical surgery best option for most ovarian cancer patients with cancer in diaphragm
In a retrospective study looking back at a decade of surgeries, Mayo Clinic Cancer Center researchers have determined that surgery to remove metastatic disease from the diaphragm, in conjunction with other procedures to remove the primary diseased tissue in ovarian cancer patients, significantly increases survival rates.
Controversies Regarding Ovarian Cancer Treatments Addressed
Trials have raised questions on the current management and standard of care for advanced ovarian cancer (AOC). These controversies highlight implications for future clinical research and policy-making, as reviewed in an article published in the International Journal of Gynecological Cancer.
More Advanced Ovarian Cancer Current Events and Advanced Ovarian Cancer News Articles
|
Business Wire : OvaRex MAb for Patients with Advanced Ovarian Cancer May Extend Remission Following Favorable Surgery and Chemotherapy. by Business Wire (Publisher) | |
|
Blood test 100% accurate: advanced test brightens hopes for ovarian cancer detection.(Clinical Rounds): An article from: Internal Medicine News by Betsy Bates (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on April 15, 2004. The length of the article is 458 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Blood test 100% accurate: advanced test brightens hopes for ovarian cancer detection.(Clinical Rounds) Author: Betsy Bates Publication: Internal Medicine News (Magazine/Journal) Date: April 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 8 Page: 14(1) Distributed by Thomson... | |
|
Advanced ovarian cancer: The role of haematopoietic growth factors (Consultant series) by Jan P Neijt (Author) | |
|
Guidance on the use of pegylated liposomal doxorubicin hydrochloride (PLDH) for the treatment of advanced ovarian cancer (Technology appraisal guidance) by National Institute for Clinical Excellence (Publisher) | |
|
Advanced ovarian cancer: The role of haematopoietic growth factors (Consultant series) by Jan P Neijt (Author) |
| © 2009 BrightSurf.com |